Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 101–200 of 1,026
Heart Failure: Diagnosis, Management and Utilization
Inamdar, A., & Inamdar, A. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5070062 · Cited by 412
The vulnerable phase after hospitalization for heart failure
Greene, S. J., Fonarow, G. C., Vaduganathan, M., Khan, S. S., Butler, J., & Gheorghiade, M. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.14 · Cited by 406
Pop-Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., Knight, C., Levi, M., Rasouli, N., & Richardson, C. R. (2022) · Diabetes Care · doi:10.2337/dci22-0014 · Cited by 399
Tromp, J., Ouwerkerk, W., van Veldhuisen, D. J., Hillege, H. L., Richards, A. M., van der Meer, P., Anand, I. S., Lam, C. S. P., & Voors, A. A. (2022) · JACC: Heart Failure · doi:10.1016/j.jchf.2021.09.004 · Cited by 401
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citation2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
Sousa-Uva*, M., Head, S. J., Milojevic, M., Collet, J.-P., Landoni, G., Castella, M., Dunning, J., Gudbjartsson, T., Linker, N. J., Sandoval, E., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx314 · Cited by 393
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (RSC) (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4083 · Cited by 395
Gorter, T. M., van Veldhuisen, D. J., Bauersachs, J., Borlaug, B. A., Celutkiene, J., Coats, A. J. S., Crespo-Leiro, M. G., Guazzi, M., Harjola, V.-P., Heymans, S., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1029 · Cited by 389
Self-citationVagus Nerve Stimulation for the Treatment of Heart Failure
Gold, M. R., Van Veldhuisen, D. J., Hauptman, P. J., Borggrefe, M., Kubo, S. H., Lieberman, R. A., Milasinovic, G., Berman, B. J., Djordjevic, S., Neelagaru, S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.525 · Cited by 391
Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda
Rohde, L. E. P., Montera, M. W., Bocchi, E. A., Clausell, N. O., Albuquerque, D. C. D., Rassi, S., Colafranceschi, A. S., Freitas Junior, A. F. D., Ferraz, A. S., Biolo, A., et al. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180190 · Cited by 377
Seferović, P. M., Polovina, M., Bauersachs, J., Arad, M., Ben Gal, T., Lund, L. H., Felix, S. B., Arbustini, E., Caforio, A. L. P., Farmakis, D., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1461 · Cited by 346
McMurray, J. J. V., Jackson, A. M., Lam, C. S. P., Redfield, M. M., Anand, I. S., Ge, J., Lefkowitz, M. P., Maggioni, A. P., Martinez, F., Packer, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044491 · Cited by 380
Self-citationZile, M. R., Claggett, B. L., Prescott, M. F., McMurray, J. J. V., Packer, M., Rouleau, J. L., Swedberg, K., Desai, A. S., Gong, J., Shi, V. C., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.931 · Cited by 375
“Although the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial was not designed to address the prognostic value of changes in NPs, the large sample size, significant event rate, effectiveness of treatment strategy, frequency of NP measur…”
Self-citationFive-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation
Stone, G. W., Abraham, W. T., Lindenfeld, J., Kar, S., Grayburn, P. A., Lim, D. S., Mishell, J. M., Whisenant, B., Rinaldi, M., Kapadia, S. R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2300213 · Cited by 369
Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002560 · Cited by 359
Self-citationMolecular Physiology of Membrane Guanylyl Cyclase Receptors
Kuhn, M. (2016) · Physiological Reviews · doi:10.1152/physrev.00022.2015 · Cited by 356
Wachter, R., Senni, M., Belohlavek, J., Straburzynska-Migaj, E., Witte, K. K., Kobalava, Z., Fonseca, C., Goncalvesova, E., Cavusoglu, Y., Fernandez, A., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1498 · Cited by 354
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease
Lee, D. I., Zhu, G., Sasaki, T., Cho, G.-S., Hamdani, N., Holewinski, R., Jo, S.-H., Danner, T., Zhang, M., Rainer, P. P., et al. (2015) · Nature · doi:10.1038/nature14332 · Cited by 353
Seferovic, J. P., Claggett, B., Seidelmann, S. B., Seely, E. W., Packer, M., Zile, M. R., Rouleau, J. L., Swedberg, K., Lefkowitz, M., Shi, V. C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30087-6 · Cited by 352
Self-citationArendse, L. B., Danser, A. H. J., Poglitsch, M., Touyz, R. M., Burnett, J. C., Llorens-Cortes, C., Ehlers, M. R., & Sturrock, E. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017129 · Cited by 339
“…(Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), showed that sacubitril/valsartan was significantly more effective for the treatment of heart failure with HFrEF compared with enalapril (McMurray et al., 2014; Mogensen et al., 2018).”
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study
Kang, D.-H., Park, S.-J., Shin, S.-H., Hong, G.-R., Lee, S., Kim, M.-S., Yun, S.-C., Song, J.-M., Park, S.-W., & Kim, J.-J. (2019) · Circulation · doi:10.1161/circulationaha.118.037077 · Cited by 340
Hollenberg, S. M., Warner Stevenson, L., Ahmad, T., Amin, V. J., Bozkurt, B., Butler, J., Davis, L. L., Drazner, M. H., Kirkpatrick, J. N., Peterson, P. N., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.001 · Cited by 336
Left ventricular hypertrophy and hypertension
Yildiz, M., Oktay, A. A., Stewart, M. H., Milani, R. V., Ventura, H. O., & Lavie, C. J. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.11.009 · Cited by 333
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2024) · European Heart Journal: Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 314
Desai, A. S., Solomon, S. D., Shah, A. M., Claggett, B. L., Fang, J. C., Izzo, J., McCague, K., Abbas, C. A., Rocha, R., Mitchell, G. F., et al. (2019) · JAMA · doi:10.1001/jama.2019.12843 · Cited by 319
Self-citationGender differences in the effects of cardiovascular drugs
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 317
Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy
Patel, A. R., & Kramer, C. M. (2017) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2017.08.005 · Cited by 313
“Despite significant treatment advances, a recently published randomized-controlled trial which included over 8,000 heart failure patients with a left ventricular ejection fraction (LVEF)<40%, a significant number of whom had some form of non-ischemic cardiomyopathy, revealed that after a median follow up of just 27 mo…”
BackgroundLee, T. M., Hsu, D. T., Kantor, P., Towbin, J. A., Ware, S. M., Colan, S. D., Chung, W. K., Jefferies, J. L., Rossano, J. W., Castleberry, C. D., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.309386 · Cited by 312
“A current study of sacubitril/valsartan in children is using a novel global rank end point as the primary outcome.(110) If successful, this may prove to be a useful end point design of future studies.”
MethodAngiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction
Solomon, S. D., Rizkala, A. R., Gong, J., Wang, W., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., et al. (2017) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.04.013 · Cited by 310
Self-citationAngiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
Pfeffer, M. A., Claggett, B., Lewis, E. F., Granger, C. B., Køber, L., Maggioni, A. P., Mann, D. L., McMurray, J. J. V., Rouleau, J.-L., Solomon, S. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104508 · Cited by 307
Self-citationTromp, J., Westenbrink, B. D., Ouwerkerk, W., van Veldhuisen, D. J., Samani, N. J., Ponikowski, P., Metra, M., Anker, S. D., Cleland, J. G., Dickstein, K., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.050 · Cited by 309
Volpe, M., Carnovali, M., & Mastromarino, V. (2015) · Clinical Science · doi:10.1042/cs20150469 · Cited by 305
Established and Emerging Roles of Biomarkers in Heart Failure
Ibrahim, N. E., & Januzzi, J. L. (2018) · Circulation Research · doi:10.1161/circresaha.118.312706 · Cited by 306
Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation
Savarese, G., Kishi, T., Vardeny, O., Adamsson Eryd, S., Bodegård, J., Lund, L. H., Thuresson, M., & Bozkurt, B. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2022.08.009 · Cited by 304
Empagliflozin in acute myocardial infarction: the EMMY trial
von Lewinski, D., Kolesnik, E., Tripolt, N. J., Pferschy, P. N., Benedikt, M., Wallner, M., Alber, H., Berger, R., Lichtenauer, M., Saely, C. H., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac494 · Cited by 303
Taqueti, V. R., Shaw, L. J., Cook, N. R., Murthy, V. L., Shah, N. R., Foster, C. R., Hainer, J., Blankstein, R., Dorbala, S., & Di Carli, M. F. (2017) · Circulation · doi:10.1161/circulationaha.116.023266 · Cited by 299
Nocturnal Hypertension: New Technology and Evidence
Kario, K. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.10971 · Cited by 298
Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease
Jia, H. (2016) · Shock · doi:10.1097/shk.0000000000000633 · Cited by 294
McDonald, M., Virani, S., Chan, M., Ducharme, A., Ezekowitz, J. A., Giannetti, N., Heckman, G. A., Howlett, J. G., Koshman, S. L., Lepage, S., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.017 · Cited by 287
Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction
Abraham, W. T., Zile, M. R., Weaver, F. A., Butter, C., Ducharme, A., Halbach, M., Klug, D., Lovett, E. G., Müller-Ehmsen, J., Schafer, J. E., et al. (2015) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.02.006 · Cited by 286
“For comparison, in a recently published HF drug trial, only 15% of patients received ICDs and 7% received CRT devices, despite a quite similar ejection fraction boundary for inclusion (19).”
ResultSelf-citationFibers for hearts: A critical review on electrospinning for cardiac tissue engineering
Kitsara, M., Agbulut, O., Kontziampasis, D., Chen, Y., & Menasché, P. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.11.014 · Cited by 283
Hallmarks of cardiovascular ageing
Abdellatif, M., Rainer, P. P., Sedej, S., & Kroemer, G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00881-3 · Cited by 274
New approaches in the treatment of hypertension
Oparil, S., & Schmieder, R. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.303603 · Cited by 276
“The Phase III Prospective Comparison of angiotensin receptor–neprilysin inhibitor with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial was a randomized double-blind trial that compared the effects of LCZ696 (200 mg twice daily) to enalapril (10 mg twice daily) in 8442 pa…”
BackgroundYancy, C. W., Januzzi, J. L., Allen, L. A., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Jessup, M., Lindenfeld, J., Maddox, T. M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.025 · Cited by 275
Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches
Heymans, S., Lakdawala, N. K., Tschöpe, C., & Klingel, K. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01241-2 · Cited by 267
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women
Dewan, P., Rørth, R., Jhund, P. S., Shen, L., Raparelli, V., Petrie, M. C., Abraham, W. T., Desai, A. S., Dickstein, K., Køber, L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.081 · Cited by 266
“received August 20, 2018; revised manuscript received Septemb Patients with Heart failure) trials were almost identical (16,17).”
BackgroundResultSelf-citationPacker, M. (2018) · Circulation · doi:10.1161/circulationaha.117.032474 · Cited by 263
Self-citationButler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab798 · Cited by 264
Self-citationThe Prevention of Hospital Readmissions in Heart Failure
Ziaeian, B., & Fonarow, G. C. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.09.004 · Cited by 260
“The novel developmental drug LCZ696 which combines an ARB with a neutral endopeptidase decreased both all-cause mortality and hospitalization when compared to an ACE inhibitor among HF patients with significant benefits observed within 30 days of randomization and market approval is pending.(27) Aldosterone inhibitors…”
Tomasoni, D., Adamo, M., Lombardi, C. M., & Metra, M. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12555 · Cited by 258
“enalapril.(40) Further, 34% of the patients who had a primary event”
BackgroundLeft Ventricular Assist Devices
Mancini, D., & Colombo, P. C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.04.039 · Cited by 254
Zile, M. R., O'Meara, E., Claggett, B., Prescott, M. F., Solomon, S. D., Swedberg, K., Packer, M., McMurray, J. J. V., Shi, V., Lefkowitz, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.042 · Cited by 254
Self-citationDiabetes, heart failure, and renal dysfunction: The vicious circles
Braunwald, E. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.003 · Cited by 254
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition
Hubers, S. A., & Brown, N. J. (2016) · Circulation · doi:10.1161/circulationaha.115.018622 · Cited by 250
“001; Figure 3).(45) There was a significant interaction between New York Heart Association class at randomization and the effect of treatment on this end point (P=0.”
BackgroundPrecision medicine in cardiology
Antman, E. M., & Loscalzo, J. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.101 · Cited by 250
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure
McMurray, J. J. V., Krum, H., Abraham, W. T., Dickstein, K., Køber, L. V., Desai, A. S., Solomon, S. D., Greenlaw, N., Ali, M. A., Chiang, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514859 · Cited by 249
Self-citationButt, J. H., Petrie, M. C., Jhund, P. S., Sattar, N., Desai, A. S., Køber, L., Rouleau, J. L., Swedberg, K., Zile, M. R., Solomon, S. D., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad083 · Cited by 247
“35,36 The institutional review boards of all participating institutions approved the protocol, and all patients gave written informed consent.”
BackgroundSelf-citationGivertz, M. M., Stevenson, L. W., Costanzo, M. R., Bourge, R. C., Bauman, J. G., Ginn, G., & Abraham, W. T. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.010 · Cited by 248
Hypertension and Heart Failure
Slivnick, J., & Lampert, B. C. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.007 · Cited by 242
“More recently, with the publication of the PARADIGM-HF trial, angiotensin-neprilysin inhibitors (ARNI) have been shown to reduce mortality in patients with HFrEF and NYHA class II–III symptoms despite above agents.(4) These promising data were reflected in the 2017 updated heart failure guidelines, which assigned a cl…”
Background2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction
Russian Society of Cardiology, (. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4103 · Cited by 244
Haynes, R., Judge, P. K., Staplin, N., Herrington, W. G., Storey, B. C., Bethel, A., Bowman, L., Brunskill, N., Cockwell, P., Hill, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034818 · Cited by 243
“89).(14) Several trials in heart failure populations, including PARADIGM-HF, suggest that”
Self-citationWang, Y., Zhou, R., Lu, C., Chen, Q., Xu, T., & Li, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012272 · Cited by 243
“Only 1 trial assessed indices using MRI,(15) and the others used echocardiography.(11,16-33)”
BackgroundMethodBurnett, H., Earley, A., Voors, A. A., Senni, M., McMurray, J. J. V., Deschaseaux, C., & Cope, S. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003529 · Cited by 238
Self-citationSenni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Reyes, A., Majercak, I., Andreka, P., Shehova-Yankova, N., Anand, I., Yilmaz, M. B., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.548 · Cited by 236
Self-citationReichart, D., Magnussen, C., Zeller, T., & Blankenberg, S. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12944 · Cited by 235
Bayes-Genis, A., Barallat, J., & Richards, A. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.04.060 · Cited by 234
Heart failure with reduced ejection fraction
Bloom, M. W., Greenberg, B., Jaarsma, T., Januzzi, J. L., Lam, C. S. P., Maggioni, A. P., Trochu, J.-N., & Butler, J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.58 · Cited by 222
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
Jhund, P. S., Fu, M., Bayram, E., Chen, C.-H., Negrusz-Kawecka, M., Rosenthal, A., Desai, A. S., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv330 · Cited by 229
Self-citationVardeny, O., Claggett, B., Packer, M., Zile, M. R., Rouleau, J., Swedberg, K., Teerlink, J. R., Desai, A. S., Lefkowitz, M., Shi, V., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.580 · Cited by 227
Self-citationBeldhuis, I. E., Lam, C. S. P., Testani, J. M., Voors, A. A., Van Spall, H. G. C., ter Maaten, J. M., & Damman, K. (2022) · Circulation · doi:10.1161/circulationaha.121.052792 · Cited by 216
2020 Clinical guidelines for Atrial fibrillation and atrial flutter
Arakelyan, M. G., Bockeria, L. A., Vasilieva, E. Y., Golitsyn, S. P., Golukhova, E. Z., Gorev, M. V., Davtyan, K. V., Drapkina, O. M., Kropacheva, E. S., Kuchinskaya, E. A., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4594 · Cited by 225
McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1548 · Cited by 222
Self-citationWilliams, B., Cockcroft, J. R., Kario, K., Zappe, D. H., Brunel, P. C., Wang, Q., & Guo, W. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08556 · Cited by 222
Health-Related Quality of Life Outcomes in PARADIGM-HF
Lewis, E. F., Claggett, B. L., McMurray, J. J. V., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Zile, M. R., Desai, A. S., et al. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003430 · Cited by 219
Self-citationSex Differences in Heart Failure With Preserved Ejection Fraction
Sotomi, Y., Hikoso, S., Nakatani, D., Mizuno, H., Okada, K., Dohi, T., Kitamura, T., Sunaga, A., Kida, H., Oeun, B., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018574 · Cited by 221
“DISCUSSION The findings of this study can be summarized as follows: In the PURSUIT- HFpEF prospective multicenter EastAsian HFpEF registry, (1) women accounted for 55.”
MethodBöhm, M., Young, R., Jhund, P. S., Solomon, S. D., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw570 · Cited by 219
“The third extension of prior findings is our demonstration of a Ushaped relationship between SBP and heart failure hospitalization (and therefore the composite of cardiovascular death or heart failure hospitalization) whereby higher hospitalization rates were observed at both ends of the SBP range included in PARADIGM…”
BackgroundResultInfluentialSelf-citation2024 Clinical practice guidelines for Hypertension in adults
Kobalava, Z. D., Konradi, A. O., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Baranova, E. I., Barbarash, O. L., Bobkova, N. V., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6117 · Cited by 211
Desai, A. S., Vardeny, O., Claggett, B., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Zile, M. R., Lefkowitz, M., Shi, V., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4733 · Cited by 217
Self-citationAbraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa943 · Cited by 217
Self-citationRecovered Heart Failure with Reduced Ejection Fraction and Outcomes: A Prospective Study
Lupón, J., Díez-López, C., de Antonio, M., Domingo, M., Zamora, E., Moliner, P., González, B., Santesmases, J., Troya, M. I., & Bayés-Genís, A. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.824 · Cited by 214
Adverse Remodeling and Reverse Remodeling After Myocardial Infarction
Bhatt, A. S., Ambrosy, A. P., & Velazquez, E. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0876-4 · Cited by 210
Mechanisms contributing to cardiac remodelling
Wu, Q.-Q., Xiao, Y., Yuan, Y., Ma, Z.-G., Liao, H.-H., Liu, C., Zhu, J.-X., Yang, Z., Deng, W., & Tang, Q.-Z. (2017) · Clinical Science · doi:10.1042/cs20171167 · Cited by 210
Racial and ethnic disparities in heart failure: current state and future directions
Lewsey, S. C., & Breathett, K. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000855 · Cited by 209
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications
Kuwahara, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107863 · Cited by 207
Metra, M., Tomasoni, D., Adamo, M., Bayes-Genis, A., Filippatos, G., Abdelhamid, M., Adamopoulos, S., Anker, S. D., Antohi, L., Böhm, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2874 · Cited by 208
2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C.-E., Tereshchenko, S., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044133 · Cited by 210
Self-citationBaroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction
Zile, M. R., Lindenfeld, J., Weaver, F. A., Zannad, F., Galle, E., Rogers, T., & Abraham, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.015 · Cited by 208
Self-citationHypertension management in patients with cardiovascular comorbidities
Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac395 · Cited by 210
Armstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study
Hicks, B. M., Filion, K. B., Yin, H., Sakr, L., Udell, J. A., & Azoulay, L. (2018) · BMJ · doi:10.1136/bmj.k4209 · Cited by 207
Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction
Brunner-La Rocca, H.-P., Linssen, G. C., Smeele, F. J., van Drimmelen, A. A., Schaafsma, H.-J., Westendorp, P. H., Rademaker, P. C., van de Kamp, H. J., Hoes, A. W., & Brugts, J. J. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.10.010 · Cited by 208
Solomon, S. D., Claggett, B., Desai, A. S., Packer, M., Zile, M., Swedberg, K., Rouleau, J. L., Shi, V. C., Starling, R. C., Kozan, Ö., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002744 · Cited by 206
Self-citationDhingra, R., & Vasan, R. S. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.07.005 · Cited by 203
“Medications and other therapies utilized currently to treat heart failure are also known to reduce BNP levels effectively; however with some exceptions (73).”
BackgroundVoors, A. A., Anker, S. D., Cleland, J. G., Dickstein, K., Filippatos, G., van der Harst, P., Hillege, H. L., Lang, C. C., ter Maaten, J. M., Ng, L., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.531 · Cited by 204
Renal sodium avidity in heart failure: from pathophysiology to treatment strategies
Mullens, W., Verbrugge, F. H., Nijst, P., & Tang, W. H. W. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx035 · Cited by 202
“mortality among chronic HF patients with reduced ejection fraction compared to an ACE-I.(96) Based on these results, Sacubitril/Valsartan received a class IB recommendation in the 2016 European guidelines”
ResultComparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction
Rørth, R., Jhund, P. S., Yilmaz, M. B., Kristensen, S. L., Welsh, P., Desai, A. S., Køber, L., Prescott, M. F., Rouleau, J. L., Solomon, S. D., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006541 · Cited by 202
“Jugular venous distension, n (%) 323 (10) 303 (9) 0.”
Self-citationB-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan
Myhre, P. L., Vaduganathan, M., Claggett, B., Packer, M., Desai, A. S., Rouleau, J. L., Zile, M. R., Swedberg, K., Lefkowitz, M., Shi, V., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.018 · Cited by 203
“Manuscript received October 31, 2018; revised manuscript received Decemb long-term efficacy and safety of sacubitril/ valsartan compared with enalapril in patients with HF with reduced ejection fraction, as previously described (5,12).”
BackgroundMethodInfluentialSelf-citationKidney Function and Outcomes in Patients Hospitalized With Heart Failure
Patel, R. B., Fonarow, G. C., Greene, S. J., Zhang, S., Alhanti, B., DeVore, A. D., Butler, J., Heidenreich, P. A., Huang, J. C., Kittleson, M. M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.002 · Cited by 204
Self-citation
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.